Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | ACR | P10323 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | XBP1 | P17861 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1973304 | 0.84 | HSD17B10 (0.47) | ELANEMAPTNPSR1SLC6A3PTGS2 | |
| SCHEMBL1282947 | 0.83 | HSD17B10 (0.50) | ELANEMAPTNPSR1SLC6A3PTGS2 | |
| SCHEMBL10045876 | 0.82 | KDM4E (0.53) | MAPTPTGS2HPGDKDM4EHSD17B10 | |
| SCHEMBL10045912 | 0.81 | MAPT (0.51) | MAPTNPSR1PTGS2HPGDXBP1 | |
| SCHEMBL29574954 | 0.78 | KDM4E (0.49) | ELANEMAPTNPSR1SLC6A3PTGS2 | |
| SCHEMBL2885742 | 0.78 | PTGS2 (0.60) | ELANEMAPTNPSR1PRSS1ACR | |
| SCHEMBL10045906 | 0.75 | MAPT (0.40) | ELANEMAPTNPSR1SLC6A3PTGS2 | |
| SCHEMBL10045893 | 0.75 | HDAC3 (0.46) | ELANEMAPTNPSR1SLC6A3PTGS2 | |
| SCHEMBL14714173 | 0.74 | MAPT (0.46) | MAPTNPSR1PRSS1ACRPTGS2 | |
| SCHEMBL15928866 | 0.74 | PTGS2 (0.43) | MAPTNPSR1PRSS1ACRPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114857-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-8114858-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2012-02-14 | — | — | US | disclosed |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-06-02 | — | — | US | disclosed |
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2011-04-28 | — | — | US | disclosed |
| US-7910568-B2 | Inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, ulcerative colitis, gastrointestinal disorders; prevention/treatment of colon cancer; releases hydrogen sulfide | ANTIBE THERAPEUTICS INC. (CA) | 2011-03-22 | — | — | US | disclosed |
| US-7879827-B2 | such as 5-amino-2-(2-Acetylamino-3-mercapto-propionyloxy)-benzoic acid, useful for the treatment of gastrointestinal disorders such as inflammatory bowel disease and irritable bowel syndrome, and for the prevention/treatment of colon cancer | ANTIBE THERAPEUTICS INC. (CA) | 2011-02-01 | — | — | US | disclosed |
| US-20090233886-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | ANTIBE THERAPEUTICS INC. (CA) | 2009-09-17 | — | — | US | disclosed |
| US-7498355-B2 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2009-03-03 | — | — | US | disclosed |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | ANTIBE THERAPEUTICS INC. (CA) | 2008-08-28 | — | — | US | disclosed |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2007-08-23 | — | — | US | disclosed |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | ANTIBE THERAPEUTICS INC. (CA) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098257-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | ELANE 3336/4885MAPT 3407/4885NPSR1 334/4885 |
| US-20080207564-A1 | Derivaitves of 4-Or 5-Aminosalicylic Acid | CBS, SI, TST | ELANE 3109/4885MAPT 2229/4885NPSR1 359/4885 |
| US-20090233886-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | ELANE 3336/4885MAPT 3407/4885NPSR1 334/4885 |
| US-20110130368-A1 | DERIVATIVES OF 4- OR 5-AMINOSALICYLIC ACID | CBS, SI, APC | ELANE 3336/4885MAPT 3407/4885NPSR1 334/4885 |
| US-20070197479-A1 | Derivatives of 4- or 5-aminosalicylic acid | CBS, SI, APC | ELANE 3336/4885MAPT 3407/4885NPSR1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.